Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression

RNA sequencing of MEK inhibitor (selumetinib)-treated tumors reveals an upregulation of the JAK/STAT3 pathway, with combinatorial therapeutic strategies of JAK/STAT3 inhibitors and selumetinib investigated for the SHH subgroup of medulloblastoma.

書誌詳細

出版年:	Communications Biology
主要な著者:	Jamie Zagozewski, Stephanie Borlase, Brent J. Guppy, Ludivine Coudière-Morrison, Ghazaleh M. Shahriary, Victor Gordon, Lisa Liang, Stephen Cheng, Christopher J. Porter, Rhonda Kelley, Cynthia Hawkins, Jennifer A. Chan, Yan Liang, Jingjing Gong, Carolina Nör, Olivier Saulnier, Robert J. Wechsler-Reya, Vijay Ramaswamy, Tamra E. Werbowetski-Ogilvie
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2022-07-01
オンライン･アクセス:	https://doi.org/10.1038/s42003-022-03654-9